In this first of a series of four sets of Homerun Slides, we review the basics of SGLT-2 inhibitors incuding Mode of Action, and Efficacy. and then look at how Canagliflozin has worked in poorly controlled type 2 diabetes patients…. To download the complete set in PowerPoint (.ppt) format, just …
Read More »FDA Approves J&J’s Invokamet Combo (SGLT-2 + Metformin)
The US Food and Drug Administration has approved Invokamet, a fixed-dose therapy combining Invokana (canagliflozin) and metformin…. Invokana, a member of the new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors, was approved in the USA as a single agent in March 2013. The thumbs-up is based …
Read More »Role of the Kidney, Part 8
In this week’s Homerun Slides, we delve into the mechanisms of action of SGLT-2 Inhibitors and look at some of the studies involving animal models and what came out of those studies…. To download the complete set of this week’s slides, just use this link: Role of the Kidney, Part 8 …
Read More »SGLT-2 Inhibitors: What Prescribers Are Saying Now
When the first SGLT-2 inhibitor came to the market we went to doctors all over the country and asked them their opinions on this new class of drugs. The overwhelming response was “wait and see.” We went back to them 3 months later and although some of them had tried …
Read More »ADA 2014 UPDATE: SGLT2-Inhibitors
There was a lot of great information at this year’s ADA Scientific Sessions on the sodium glucose co-transporter 2 (SGLT2) inhibitors both alone and in combination with other medications, and we have a review for you. Canagliflozin Canagliflozin has demonstrated improvement in glycemic control, body weight, and blood pressure across …
Read More »Can SGLT-2 Inhibitors Offer a Better Approach in Type 2 Diabetes?
Available studies to date looking at the benefits of using SGLT-2 inhibitors have shown positive results…. The discovery of sodium-glucose co-transporter 2 (SGLT2) inhibitors, with a novel mechanism independent of insulin secretion or sensitization, offered a new therapeutic approach for the management of type 2 diabetes mellitus. The aim of this …
Read More »Dr. Stanley Schwartz: Thoughts on SGLT-2 Inhibitors
Our publisher, Steve Freed, had a chance to talk with Dr. Stanley Schwartz, asking questions and getting some in-depth and very informative answers on exactly how SGLT-2 Inhibitors work. Steve Freed: Regarding the SGLT2 drugs that are now available, I know that a lot of physicians just refuse to write …
Read More »Obesity 2014 – New Medical Therapies, Part 8
In this Homerun Slides series, we review some issues around the Diabetic Management of the Obese Patient including; Potential Causes of Weight Gain with Treatment of Type 2 Diabetes; Weight Reduction Issues – Non-Insulin; and treatment with SGLT-2 Inhibitors with Incretins (GLP-1’s or DPP-IV’s)…. See more SGLT-2 Resources To download …
Read More »SGLT2 Inhibition: A Novel Treatment Strategy for Type 2 Diabetes
In this special feature for our series on SGLT2 inhibitors, we are extremely pleased to present this comprehensive slide series from the WorldWIDE Initiative for Diabetes Education. In this subset of their series, the Role of the Kidneys is examined and the effects of SGLT2 inhibitors is explained….
Read More »Surprising Trends in the Use of Antidiabetic Drugs
Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.